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In Brief
Kudirka et al. present a new
bioconjugation technique that proceeds
rapidly at neutral pH without a catalyst.
The reaction, a Knoevenagel
condensation variant, forms a stable C-C
bond between protein and payload.
Using this technique, they generated an
antibody-drug conjugate that
demonstrates excellent efficacy.
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There is a need for facile chemistries that allow for
chemo- and regioselectivity in bioconjugation reac-
tions. To address this need, we are pioneering site-
specific bioconjugation methods that use formylgly-
cine as a bioorthogonal handle on a protein surface.
Here we introduce aldehyde-specific bioconjugation
chemistry, the trapped-Knoevenagel ligation. The
speed and stability of the trapped-Knoevenagel liga-
tion further advances the repertoire of aldehyde-
based bioconjugations and expands the toolbox for
site-specific protein modifications. The trapped-
Knoevenagel ligation reaction can be run at near
neutral pH in the absence of catalysts to produce
conjugates that are stable under physiological condi-
tions. Using this new ligation, we generated an anti-
body-drug conjugate that demonstrates excellent
efficacy in vitro and in vivo.
INTRODUCTION
The current bioconjugation reactions that underpin proteinmodi-
fication rely largely on nonspecific, promiscuous chemistries that
exploit the reactive amino acid side chains of Glu, Asp, Lys, or
Cys residues (Sletten and Bertozzi, 2009; Stephanopoulos and
Francis, 2011). These chemistries result in nonspecific conjuga-
tion atmultiple sites, producing a polydispersemixture of labeled
proteins. For example, antibody-drug conjugates (ADCs) that are
produced using conventional methods comprise a mixture of
products with drug-to-antibody ratios (DARs) ranging from 0 to
8 (Kim et al., 2014). These heterogeneous mixtures contain sub-
populations that exhibit variable potency and pharmacokinetics
(Hamblett et al., 2004). Furthermore, the high DAR subpopula-
tions tend to show enhanced toxicity relative to lower DAR con-
stituents (Hamblett et al., 2004). Due to their complexity, conven-
tional ADCs require complicated analytics and are challenging to
manufacture reproducibly (Stephan et al., 2008; Kim et al., 2014;
Wakankar et al., 2014). These problems are being addressed
with a variety of newer site-specific ligation techniques (Axup
et al., 2012; McDonagh et al., 2006; Junutula et al., 2008; Jeffrey
et al., 2013; Toda et al., 2013; Panowksi et al., 2014).Chemistry & Biology 22, 293Current site-specific bioconjugation methods rely on either
the introduction of a nonnative amino acid or a short peptide
tag in the protein backbone providing the necessary bio-
orthogonal handle to undergo selective and specific reactions
(Rabuka, 2010; Axup et al., 2012; Strop et al., 2013; Patterson
et al., 2014; Zhou et al., 2014; Zimmerman et al., 2014). Among
these, aldehydes represent a versatile chemical moiety because
their electrophilic nature allows for selective reactivity with nucle-
ophiles in the presence of native amino acids (Carrico, 2008). We
have developed a chemoenzymatic approach for the site-spe-
cific introduction of aldehydes that relies on the naturally occur-
ring formylglycine-generating enzyme (FGE) (Carrico et al., 2007;
Wu et al., 2009; Rabuka et al., 2012). FGE introduces a formylgly-
cine (fGly) residue into a protein scaffold through the selective
oxidation of a thiol embedded in the FGE recognition sequence,
which can then be chemically modified (Figure 1A).
Previously, we reported the development of the Hydrazino-
iso-Pictet-Spengler (HIPS) ligation, which harnesses a traditional
ligation technique—hydrazone formation—to generate a tran-
sient intermediate that is subsequently trapped with a carbon-
based nucleophile, resulting in a stable C-C bond (Agarwal
et al., 2013). Seeking additional means to form C-C bonds be-
tween protein and payload while retaining the enhanced nucleo-
philicity of a-effect nucleophiles, we explored the possible use of
carbon nucleophiles in bioconjugation reactions (Leonard et al.,
2011; Truong et al., 2011). We reasoned that stabilized carban-
ions would readily react with formylglycine at physiological pH
without the use of catalysts, which are often employed with ami-
nooxy or hydrazide ligations (Dirksen and Dawson, 2008; Wend-
eler et al., 2014). To this end, we focused on the Knoevenagel
condensation (Knoevenagel, 1898; Deb and Bhuyan, 2005),
which involves a reaction between a stabilized carbanion and a
carbonyl compound, followed by dehydration to produce an
enone (Figure 1B).RESULTS AND DISCUSSION
Examination of the literature revealed that 1-phenyl-3-methyl-5-
pyrazolone has been used for the derivatization of carbohydrates
(Honda et al., 1989). The pyrazolone reacts with reducing sugars
under mild conditions in water, making the pyrazolone an ideal
carbon nucleophile candidate for bioconjugation with alde-
hyde-tagged proteins. Notably, Honda et al. (1989) reported
that the reaction of sugars with pyrazolone primarily led to the–298, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 293
Figure 1. Overview of the Trapped-Knoeve-
nagel Ligation Using a Thiopyrazolone
Nucleophile
(A) Generation of C-terminally tagged aHER2-thi-
oPz-ADC.
(B) Reaction of a model thiopyrazolone 1
to generate tetrahydrothiopyranopyrazolone 2,
through the enone generated via a Knoevenagel
condensation.isolation of double addition products. This observation suggests
that the rate of the second pyrazolone addition into the enone in-
termediate is faster than the first addition into an aldehyde. We
reasoned that the diadduct formed via an intermolecular reaction
could be overcome by trapping the intermediate enone with a
second intramolecular nucleophile.
After considering several designs and nucleophiles, we pre-
pared a pyrazolone moiety containing a pendant ethylenethiol
(1) that would trap the enone resulting from the first addition
via a 6-endo-trig cyclization (Figure 1). To confirm the final liga-
tion product, we tested the pyrazolone conjugation with two
model small molecules bearing an aldehyde, benzyloxyacetal-
dehyde and benzaldehyde. Reaction of compound 1 (thioPz)
with the respective aldehydes in aqueous solution at pH 7.4
overnight afforded compounds 2a and 2b, which upon purifica-
tion were characterized bymass spectrometry and nuclear mag-
netic resonance (NMR). Importantly, NMR confirmed cyclization
as indicated by the chemical shift of the single methine proton at
d 4.09 and 4.88 for the benzyloxacetaldehyde$thioPz adduct 2a
and the benzaldehyde$thioPz adduct 2b, respectively. Next, we
set out to examine this reaction on a peptide containing fGly in
the context of the native FGE recognition sequence. Reaction
of compound 1 with H2N-GPSVFPL(fGly)TPSR-OH at pH 7.2
was carried out for 12 hr. Formation of the desired product along
with the absence of the fGly peptide starting material was
observed by mass spectrometry (Figure S1 available online).
With the thiopyrazolone (thioPz) ligation reaction validated in
two model systems, we set out to synthesize a thioPz intermedi-
ate (5) that could be readily appended to a variety of potential
payloads, including cytotoxic compounds commonly used with
ADCs (Figure 2). Using a modification of the procedure reported
by Oikawa et al. (1978), b-ketoester 3 was obtained as a crystal-
line solid in 73% yield over two steps without purification from
the commercially available 3-(tritylthio)propionic acid. Reaction
of b-ketoester 3 with ethyl hydrazinoacetate afforded the trityl-
protected thiopyrazolone 4 in 87% yield. Compound 4 was
saponified to obtain a 71% yield of the desired acid 5 as the
enol tautomer. Compound 5, synthesized in four operationally
simple steps, can be readily coupled to a variety of payloads
via its acid handle. All thioPz constructs were stored in their pro-
tected forms and deprotected just prior to conjugation.294 Chemistry & Biology 22, 293–298, February 19, 2015 ª2015 Elsevier Ltd All rights reservIn recent years ADCs, exemplified by
trastuzumab emtansine (Kadcyla) and
brentuximab vedotin (Adcetris), highlight
the growing importance of bioconjugates
as oncology therapeutics (Senter and
Sievers, 2012; Trail, 2013). An ADC com-
bines the high potency of cytotoxicchemotherapy with the targeted delivery and long circulating
half-life of a monoclonal antibody, resulting in a molecule with
improved efficacy and a greater therapeutic index relative to
the free cytotoxic payload. It is becoming increasingly clear
that the choice of bioconjugation chemistry and the physico-
chemical properties of the linker play critical roles in defining
the biological behavior of these conjugates (Alley et al., 2008).
Therefore, we elected to demonstrate the utility of our conjuga-
tion chemistry in the context of an ADC using maytansine as
the cytotoxic payload.
We evaluated the trapped-Knoevenagel ligation by creating a
site-specific ADC using a formylglycine-tagged aHER2 antibody
and a maytansine payload functionalized with either thioPz,
construct 6, or aminooxy, construct 7 (Figure 2). The production
and characterization of fGly-modified aHER2 has been previ-
ously described (Hudak et al., 2012). The thioPz ligation pro-
ceeds rapidly across all pHs tested in the absence of any catalyst
(Figure 3). In addition, we compared the thioPz ligation with
oxime formation, the latter reaction commonly used in fGly
conjugation (Carrico et al., 2007). The thioPz reaction was faster
than oxime ligation even under acidic conditions, which are
optimal for oxime formation (Jencks, 1959; Kalia and Raines,
2008; Gudmundsdottir et al., 2009). Notably, at pH 7.0 after
2 hr the thioPz ligation consumed 83% of the starting material,
whereas at pH 4.6, optimal for oxime formation, only 12% of
the starting material was consumed. At 1 mMmaytansine-linker,
the pseudo-first-order rate constants for these reactions at their
optimal pHs were 2.90 3 102 and 3.87 3 101 M1 s1 for
oxime and thioPz ligations, respectively. However, as the
optimal pH for oxime formation is neither physiologically
relevant nor protein friendly, the more relevant comparison is
the pseudo-first-order rate constants at pH 6.0: 9.27 3 103
and 1.973 101 M1 s1 for oxime and thioPz ligations, respec-
tively. Progress of conjugation was tracked by hydrophobic
interaction chromatography (HIC) (Figure S2).
In a panel of control experiments, the native aHER2 antibody,
without an aldehyde tag sequence, was subjected to compound
6 under a variety of pHs. These control experiments showed no
evidence for the addition of the maytansinoid construct to the
antibody, demonstrating that the pendant thiol in thioPz did not
react with the native disulfides in the antibody and that theed
Figure 2. Building Block Synthesis and Conjugation Constructs
(A) Synthetic route to thioPz building block.
(B) Structures of thioPz-maytansine construct (6) and aminooxy-maytansine
construct (7).
Figure 3. ThioPz Conjugation Is Faster Than Aminooxy Conjugation
with fGly-Tagged Antibodies across a Variety of pH Values
The fGly-aHER2 antibody (1.9mgml1) was conjugated to thioPz compound 6
(1 mM) or aminooxy compound 7 (1 mM) at 37C in 100mM sodium citrate (pH
5–7) or 100 mM potassium acetate (pH 4.6), 25 mM sodium chloride in the
presence of 1% dimethyl adipimidate (DMA), and 0.25% Triton X-100.
Analytical HIC was used to monitor the disappearance of starting material.conjugation chemistry required the presence of the aldehyde
(Figure S3). Furthermore, we took advantage of the unbiased,
highly-sensitive capabilities of peptide mapping by liquid chro-
matography-tandem mass spectrometry to probe chemical
modification of the protein at the amino acid level. The resulting
data demonstrated that the ligation occurred only at the alde-
hyde; all other amino acids remained unmolested. Specifically,
the analysis consisted of proteolytically digesting the sample
and then identifying all of the observed peptides along with
any posttranslational or chemical modifications (e.g., conjugated
payloads) that were present. The identified peptides covered
98.6% and 95.4% of the aHER2 light and heavy chains, respec-
tively. The thioPz adduct was detected on the aldehyde tag con-
taining peptide with an error of <4 ppm (Figure S4), confirming
that the conjugation resulted in the anticipated product. Impor-
tantly, the thioPz adduct was not observed on any other peptides
in the antibody, demonstrating the specificity of the trapped-
Knoevenagel ligation in the context of a complex protein
environment.
The thioPz ligation generates a tetrahydrothiopyranopyrazo-
lone, creating a C-C bond between the antibody and theChemistry & Biology 22, 293payload. Traditional carbonyl ligation techniques involve the
formation of oximes; however, the stability of the oxime link-
ages can be context dependent. Therefore, we were interested
in comparing the stability of the thioPz ADC with an ADC con-
jugated using an oxime linkage. We evaluated the stability of
these conjugates in human plasma using a sandwich ELISA
(Figure 4). The aHER2-thioPz-ADC conjugate underwent mini-
mal (13%) hydrolysis over the course of 7 days at 37C, con-
firming the stability of the conjugate in a biological matrix.
This measurement corresponded to a 35 day in vitro half-life
in plasma, which is especially impressive when contrasted
with the observed half-life of the fGly-derived oxime conjugate
(t1/2 <1 day).
Having demonstrated that we could generate a stable linkage
between the antibody and cytotoxic payload, we tested the
in vitro efficacy of our aHER2-thioPz-ADC. As a positive con-
trol, we used free maytansine and included an isotype control
ADC made using the same maytansine thioPz linker (6) as a
negative control. The fGly-containing antibodies were conju-
gated to thioPz-Glu-PEG2-maytansine (6) at 15 mg ml1 and
8 drug:antibody equivalents for 16 hr at 37C in 50 mM sodium
citrate, 1 mM EDTA, and 50 mM NaCl (pH 5.5) in the presence
of 0.85% DMA and 0.085% Triton X-100. These conditions
were employed to optimize antibody stability, which is optimal
at acidic pH. Free drug was removed using tangential flow
filtration. Then unconjugated antibody was removed using pre-
parative HIC. To determine the DAR of the final products, ADCs
were examined by analytical HIC; to monitor aggregation, sam-
ples were analyzed by size-exclusion chromatography. Final
products comprised <5% aggregate. The aHER2 ADC showed
potent dose-dependent cytotoxicity that was similar to that of
free maytansine (Figure 5A), demonstrating that the ADC was
efficiently internalized and that the cytotoxic payload was
active when modified with the linker. By contrast, the isotype-
thioPz-ADC had no effect on cell growth at the doses adminis-
tered. Next, we examined the in vivo efficacy of aHER2-thioPz-
ADC against an NCI-N87 gastric tumor xenograft in SCID mice.
When the engrafted tumors reached an average size of–298, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 295
Figure 4. Conjugations with the Trapped-Knoevenagel Ligation Are
Stable in Plasma at 37C
ADCs made by conjugating C-terminally tagged aHER2 with either a thioPz-
maytansine (6) or an aminooxy-maytansine payload (7) were spiked into hu-
man plasma and incubated at 37C for up to 1 week. Samples were analyzed
by ELISA for anti-maytansine and anti-human Fc reactivity. The ratio of the two
signals was used as a measure of conjugation. The oxime conjugate de-
composed rapidly, with a t1/2 of <1 day (blue). By contrast, the thioPz conju-
gate demonstrated minimal loss (13%) of conjugate during the course of the
experiment, corresponding to a t1/2 of 35 days (green). Error bars indicate the
SD of four technical replicates.
Figure 5. The aHER2 ADC Made Using the Trapped-Knoevenagel
Ligation Is Highly Active In Vitro and In Vivo against the HER2-Over-178 mm3, animals were dosed intravenously (5 mg kg1 of
ADC) once a week for 4 weeks. Negative controls included
an isotype-thioPz-ADC, untagged aHER2 antibody, and vehicle
alone. As shown in Figure 5B, weekly treatment with aHER2-
thioPz-ADC was highly effective in this tumor model, resulting
in durable tumor regression lasting >30 days after the last
dose was administered.expressing NCI-N87 Tumor Model
(A) In vitro cytotoxicity. NCI-N87 cells were treated with varying concen-
trations of aHER2-thioPz-ADC (green), isotype ADC (blue), or free may-
tansine (black). After a 6 day incubation period, cell viability was assessed
using CellTiter Glo. IC50 values were determined using GraphPad Prism.
Error bars represent the SD of nine biological replicates of three technical
replicates.
(B) In vivo efficacy. SCID mice bearing NCI-N87 tumors on their flank were
dosed (5 mg kg1 of ADC) with aHER2-thioPz-ADC (green) once a week for
4 weeks. An isotype control ADC (blue), untagged aHER2 antibody (orange),
and vehicle alone (gray) were used as negative controls. Error bars indicate the
SEM; n = 8 mice per group.SIGNIFICANCE
Here, we have developed a new bioconjugation technique
that can be carried out at neutral pH in the absence of cata-
lyst. Our reaction exemplifies a carbonyl ligation method
that uses a carbon-based nucleophile. Specifically, the
pyrazolone nucleophile undergoes a Knoevenagel conden-
sation to generate an enone, which is then trapped via a
pendant thiol nucleophile. We have shown that bio-
conjugates made with tetrahydrothiopyranopyrazolone
linkers have excellent stability in plasma, and that this conju-
gation can be successfully applied to the creation of highly
potent and stable ADC constructs. We believe that the thi-
oPz ligation—with its unique combination of speed, stability,
and facile synthesis—will prove useful to the bioconjugation
community for both research and applied purposes.
EXPERIMENTAL PROCEDURES
General Bioconjugation Conditions
The fGly-aHER2 antibody was conjugated to thioPz-Glu-PEG2-maytansine
(6) at 15 mg ml1 and eight drug:antibody equivalents for 16 hr at 37C
in 50 mM sodium citrate, 1 mM EDTA, and 50 mM NaCl (pH 5.5) in
the presence of 0.85% DMA and 0.085% Triton X-100. Free drug was296 Chemistry & Biology 22, 293–298, February 19, 2015 ª2015 Elseremoved using tangential flow filtration. Then, unconjugated antibody
was removed using preparative HIC (GE Healthcare 17-5195-01) with mo-
bile phase A: 1.0 M ammonium sulfate/25 mM sodium phosphate (pH 6.8),
and mobile phase B: 25% isopropanol, 18.75 mM sodium phosphate
(pH 6.8). An isocratic gradient of 33% B was used to elute unconjugated
material, followed by a linear gradient of 41%–95% B to elute mono-
and diconjugated species. The separated mono- and diconjugated mate-
rial was buffer exchanged. To determine the DAR of the final product,
ADCs were examined by analytical HIC (Tosoh #14947) with mobile
phase A: 1.5 M ammonium sulfate, 25 mM sodium phosphate (pH 7.0),
and mobile phase B: 25% isopropanol, 18.75 mM sodium phosphate
(pH 7.0). To monitor aggregation, samples were analyzed using size-exclu-
sion chromatography (Tosoh #08541) with a mobile phase of 300 mM
NaCl, 25 mM sodium phosphate (pH 6.8).vier Ltd All rights reserved
Control Reaction of 6 with aHER2
A nonaldehyde-tagged aHER2 antibody was subjected to thioPz-Glu-PEG2-
maytansine (6) at 1 mg ml1 and 368 drug:antibody equivalents for 16 hr at
37C in 50 mM sodium citrate and 50 mMNaCl (pH 5.5, 6.5, or 7.2) in the pres-
ence of 2.5%DMAand 0.25%Triton X-100. Free drugwas removed using spin
filtration, and the reaction mixture was analyzed using analytical HIC using the
method described in the general bioconjugation procedure. See Figure S1.
Rate Constant Determination
As shown in Figure 3, aldehyde tag containing aHER2 antibody (25 mM total
fGly) was conjugated with thioPz compound 6 (1 mM) or aminooxy compound
7 (1 mM). Analytical HIC was used to monitor the disappearance of starting
material. Apparent reaction velocities (vapp) were determined from nonlinear
regression of the reaction progress versus time. Pseudo-first-order rate con-
stants were calculated from vapp using the standard formula:
vapp = k½A½B= kapp½B
where k is the true second-order rate constant for the reaction of A (thioPz) and
B (fGly), and kapp is the pseudo-first-order rate constant, in cases where [A] is
significantly higher than [B]. In this case the ratio of A/B is 40.
In Vitro Stability
ADCs were spiked into human plasma at 1 pmol (drug) ml1. The sam-
ples were aliquoted and stored at 80C until use. Aliquots were placed
at 37C under 8% CO2 for the indicated times, and then were analyzed
by ELISA to assess the anti-maytansine and anti-Fab signals. A freshly
thawed aliquot was used as a reference starting value for conjugation. In
brief, ADCs were captured on HER2 His-coated plates, then detected
with either an anti-maytansine antibody followed by a horseradish peroxi-
dase-conjugated secondary, or with a directly conjugated anti-human Fc-
specific antibody. Bound antibody was visualized with 3,30,5,50-tetrame-
thylbenzidine (TMB) substrate. The colorimetric reaction was stopped
with H2SO4, and the absorbance at 450 nm was determined using a plate
reader. Data analysis was performed in Excel. Each sample was analyzed
in quadruplicate, and the average values were used. The ratio of anti-may-
tansine signal to anti-Fab signal was used as a measure of antibody
conjugation.
In Vitro Cytotoxicity Assay
The HER2-positive breast carcinoma cell line is maintained in RPMI-1640 me-
dium (Cellgro) supplemented with 10% fetal bovine serum (Invitrogen) and
Glutamax (Invitrogen). Twenty-four hours prior to plating, cells are passaged
to ensure log-phase growth. On the day of plating, 5000 cells are added per
well into 96-well plates in 90 ml of normal growth medium supplemented
with 10 IU of penicillin and 10 mg ml1 streptomycin (Cellgro). Cells are treated
at various concentrations with 10 ml of diluted drug/linkers or ADCs, and incu-
bated at 37C. After 6 days of incubation, 100 ml per well of Cell Titer-Glo re-
agent (Promega) is added and luminescence is measured on a plate reader.
GraphPad Prism software is used for data analysis, including calculation of
IC50s.
Xenograft Studies
This study was approved by the Charles River Laboratories Institutional Animal
Care and Use Committee.
Female C.B-17 SCID mice were inoculated subcutaneously with 1 3 107
NCI-N87 tumor cells in 50% Matrigel. When the tumors reached an average
of 112 mm3, the animals were given a single 5 mg ml1 dose of ADC, trastuzu-
mab antibody (untagged), or vehicle alone. The animals were monitored twice
weekly for body weight and tumor size. Tumor volume was calculated using
the formula
Tumor volume ðmm3=w
2 3 l
2
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